Furosemide Mabo 40 mg tablets EFG

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Furosemide Mabo 40 mg tablets EFG

Read the entire leaflet carefully before you start taking this medicine, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, since it could harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if the effects are not listed in this leaflet. See section 4.

Leaflet contents:

1. What Furosemida Mabo is and what it is used for
2. What you need to know before taking Furosemida Mabo
3. How to take Furosemida Mabo
4. Possible adverse effects
5. How to store Furosemida Mabo
6. Contents of the pack and other information

1. What Furosemida Mabo is and what it is used for

Furosemida is a diuretic belonging to the sulfonamide group. It works by increasing urine elimination (diuretic effect) and reducing blood pressure (antihypertensive effect).

Always under the prescription of your doctor, this medicine is indicated for the treatment of:

• Edema (swelling due to fluid accumulation) associated with congestive heart failure, hepatic cirrhosis (ascites), and kidney disease, including nephrotic syndrome (treatment of the underlying disease takes priority).
• Edema following burns.
• Mild to moderate arterial hypertension.

2. What you need to know before starting to take Furosemide Mabo

Read carefully the instructions provided in section 3, “How to take Furosemide Mabo”.

Do not take Furosemide Mabo

• If you are allergic to furosemide, to medicines of the furosemide type (sulfonamides), or to any of the other components of this medicine (listed in section 6).

• If you have a decreased total blood volume (hypovolemia) or are dehydrated.

• If you have severe kidney problems associated with a marked reduction in urine output (renal failure with anuria) that do not respond to this medicine.

• If you have severely low levels of potassium in your blood (severe hypokalemia) (see section 4, “Possible side effects”).

• If you have a severe deficiency of sodium salts in your blood (severe hyponatremia).

• If you are in a pre-comatose or comatose state associated with hepatic encephalopathy.

• If you are breastfeeding a baby.

• If you are pregnant, see section “Pregnancy, lactation and fertility”.

Warnings and precautions

Consult your doctor or pharmacist before starting to take furosemide.

Take special care with this medicine:

• If you have problems with urine elimination, especially at the beginning of treatment.
• If you have low blood pressure (hypotension).
• If you are at special risk of experiencing a marked drop in blood pressure (e.g., in patients with significant coronary or cerebral stenosis).
• If you have latent or overt diabetes mellitus.
• If you suffer from gout.
• If you have severe kidney problems associated with severe liver disease (hepatorenal syndrome).
• If your blood protein levels are low (hypoproteinemia), especially if you also have, for example, nephrotic syndrome (see section 4. “Possible adverse effects”).
• In premature children (see section 4. “Possible adverse effects”).
• There is a possibility of exacerbation or activation of systemic lupus erythematosus.
• If you are elderly, if you are being treated with medicines that may cause low blood pressure, or if you have other medical conditions associated with a risk of low blood pressure.

During your treatment with this medicine, periodic monitoring of blood levels of sodium, potassium, and creatinine is generally required, especially if you experience significant fluid loss due to vomiting, diarrhea, or excessive sweating. Dehydration or hypovolemia, as well as any significant electrolyte or acid-base imbalances, should be corrected. Treatment interruption may be necessary.

Elderly patients with dementia who are taking risperidone should exercise special caution when using risperidone and furosemide concomitantly. Risperidone is a medicine used to treat certain mental disorders, such as dementia (a disease characterized by several symptoms: memory loss, speech difficulties, thinking problems).

The input is empty. Please provide the text you would like translated.

Use in athletes

This medicine contains furosemide, which may produce a positive result in doping control tests.

Use of Furosemide Mabo with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

The effect of treatment may be affected if furosemide is used at the same time as other medicines.

Some substances may have increased toxicity in the ear or kidneys when administered together with this medicine. Therefore, they should only be used together if there are specific medical reasons to do so.

These substances include:

• Aminoglycoside antibiotics (medicines for infections) such as gentamicin, kanamycin, and tobramycin.
• Medicines for cancer (cisplatin).

Your doctor may need to adjust your dose and/or take other precautions if you are taking any of the following medicines:

• Aliskiren – used to treat high blood pressure.

Concomitant use of furosemide with other medicines may weaken the effect of these medicines, such as:

• Medicines used for diabetes (antidiabetics).
• Medicines used to raise blood pressure (vasopressor sympathomimetics, for example, epinephrine and norepinephrine).

In other cases, concomitant use may increase the effects of these medicines, such as:

• Medicines for asthma (theophylline).
• Muscle relaxants of the curare type.
• Medicines for depression (lithium salts): may increase the risk of lithium toxicity, including the risk of harmful effects on the heart or brain.
• Patients receiving diuretic treatment may experience severe hypotension and worsening of kidney function, especially when an ACE inhibitor (Angiotensin-Converting Enzyme inhibitor) or an angiotensin II receptor antagonist is initiated for the first time or when a high dose is administered for the first time.
• If medicines used to treat high blood pressure, diuretics, or other medicines that may lower blood pressure are administered together with furosemide, a more pronounced drop in blood pressure should be anticipated.
• Medicines that are toxic to the kidneys: concomitant administration may enhance the harmful effects of these medicines on the kidneys.

Some medicines for inflammation and pain (non-steroidal anti-inflammatory drugs, including acetylsalicylic acid) and medicines for epilepsy (phenytoin) may reduce the effect of furosemide.

Furosemide may increase the toxicity of salicylates.

This medicine and sucralfate should not be administered together within less than a 2-hour interval, as the effect of furosemide may be reduced.

Medicines such as probenecid and methotrexate, or other medicines that are significantly eliminated by the kidneys, may reduce the effect of furosemide. When used at high doses, they may increase serum levels and raise the risk of adverse effects due to furosemide or concomitant administration.

The following substances may increase the risk of lowering potassium levels in the blood (hypokalemia) when administered with furosemide:

• Medicines for inflammation (corticosteroids).
• Carbenoxolone (a medicine used to treat oral mucosal lesions).
• Large amounts of liquorice.
• Prolonged use of laxatives for constipation.

Some electrolyte imbalances (e.g., decreased blood levels of potassium (hypokalemia) or magnesium (hypomagnesemia)) could increase the toxicity of certain medicines (e.g., digitalis medicines and medicines that induce QT interval prolongation syndrome).

Patients receiving furosemide and high doses of certain cephalosporins (antibiotics) may experience reduced kidney function.

Concomitant administration of furosemide and cyclosporine A (a medicine used to prevent transplant rejection) is associated with an increased risk of gouty arthritis (joint inflammation) secondary to elevated blood urea levels (hyperuricemia) and impaired kidney excretion of urea.

Patients at high risk of contrast-induced nephropathy (kidney disease) who receive furosemide are more likely to experience deterioration in kidney function.

Administration of furosemide together with risperidone in elderly patients with dementia may increase mortality.

High doses of furosemide administered with levothyroxine may lead to an initial transient increase in free thyroid hormones, followed by a general decrease in total thyroid hormone levels.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

If you are pregnant, you should only use furosemide if there are medical reasons requiring it.

Furosemide must not be administered during breastfeeding. If its administration is considered essential, your doctor may require you to discontinue breastfeeding, as furosemide passes into breast milk.

Driving and use of machines

This medicine may cause dizziness or drowsiness. This is more likely at the beginning of treatment, when your doctor increases your dose, or if you consume alcohol. Do not drive or operate tools or machinery if you feel dizzy or drowsy.

Some adverse effects (e.g., an undesirable marked drop in blood pressure) may impair your ability to concentrate and react, and therefore pose a risk in situations where these skills are particularly important (e.g., operating vehicles or machinery).

Furosemide Mabo contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per tablet; thus, it is essentially "sodium-free".

3. How to take Furosemida Mabo

Follow exactly the instructions for use of this medicine given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Remember to take your medicine.

Take this medicine on an empty stomach, swallowing it without chewing and with a sufficient amount of liquid.

If you think that the effect of this medicine is too strong or too weak, inform your doctor or pharmacist.

Your doctor will prescribe the lowest dose sufficient to achieve the desired effect.

In adults, treatment should be started with half, one, or two tablets (20 to 80 mg of furosemide) daily. The maintenance dose is half to one tablet per day, and the maximum dose will be determined by your doctor and depends on your response to treatment.

Use in children

In infants and children, a daily dose of 2 mg/kg body weight is recommended, up to a maximum of 40 mg per day.

Your doctor will indicate how long your treatment with this medicine should last. Do not stop treatment prematurely.

If you take more Furosemida Mabo than you should

In case of overdose or accidental ingestion, consult your doctor immediately or go to the nearest hospital emergency department, taking this leaflet with you, or call the Toxicology Information Service at telephone number 91 562 04 20, indicating the medicine and the amount ingested.

An accidental overdose could lead to a severe drop in blood pressure (which may progress to shock), kidney problems (acute renal failure), coagulation disorders (thrombosis), delirium, flaccid paralysis affecting soft muscles, apathy, and confusion.

No specific antidote is known.

In case of overdose, treatment will be based on the symptoms.

If you forget to take Furosemida Mabo

Do not take a double dose to make up for forgotten doses.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Adverse effects have been grouped according to their frequency:

Very common (may affect more than 1 in 10 patients)

• electrolyte disturbances (including symptomatic cases), dehydration and decreased total blood volume (hypovolemia), particularly in elderly patients, elevated creatinine and triglyceride levels in blood.

Common (may affect up to 1 in 10 patients)

• decreased levels of sodium (hyponatremia), chloride (hypochloremia), potassium (hypokalemia); increased levels of cholesterol and uric acid in blood; and gout attacks.
• increased urine volume.
• mental disturbances (hepatic encephalopathy) in patients with liver problems (hepatocellular insufficiency).
• increased blood viscosity (hemoconcentration).

Uncommon (may affect up to 1 in 100 patients)

• impaired glucose tolerance. Latent diabetes mellitus may become apparent.
• nausea.
• hearing disorders, usually transient, particularly in patients with renal insufficiency, decreased blood protein levels (hypoproteinemia) and/or following too rapid intravenous administration of furosemide. Deafness (sometimes irreversible).
• itching, rash, eruptions, blisters and other more severe reactions such as erythema multiforme, pemphigoid, exfoliative dermatitis, purpura and photosensitivity reactions.
• decreased platelet levels (thrombocytopenia).

Rare (may affect up to 1 in 1,000 patients)

• allergic inflammation of blood vessels (vasculitis).
• allergic-type kidney reaction (tubulointerstitial nephritis).
• vomiting, diarrhea.
• subjective sensation of ringing in the ears (tinnitus).
• severe allergic reactions (anaphylactic or anaphylactoid reactions) (e.g. with shock).
• tingling sensation in the limbs (paresthesia).
• decreased white blood cell count (leukopenia), increased levels of a type of white blood cells, eosinophils (eosinophilia).
• fever.

Very rare (may affect up to 1 in 10,000 patients)

• inflammation of the pancreas (acute pancreatitis).
• liver disorder (cholestasis), increased liver enzymes (transaminases).
• decreased levels of a type of white blood cells, granulocytes (agranulocytosis), decreased number of red blood cells (aplastic anemia or hemolytic anemia).

Frequency not known (cannot be estimated from available data)

• decreased levels of calcium (hypocalcemia), magnesium (hypomagnesemia), increased blood urea levels, metabolic alkalosis, pseudo-Bartter syndrome in cases of misuse and/or prolonged use of furosemide.

• blood coagulation disorders (thrombosis).

• increased levels of sodium and chloride in urine, urinary retention (in patients with partial obstruction of urinary flow), formation of kidney stones (nephrocalcinosis/nephrolithiasis) in premature infants, renal failure.

• severe blistering skin and mucosal reactions (Stevens-Johnson syndrome), serious skin disorder characterized by blistering and exfoliative lesions (toxic epidermal necrolysis), acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), lichenoid reactions characterized by small, itchy, reddish-purple, polygonal lesions appearing on the skin, genitals or mouth.

• exacerbation or activation of systemic lupus erythematosus.

• dizziness, fainting and loss of consciousness, headache.

• cases of rhabdomyolysis have been reported, frequently in cases associated with severe hypokalemia (low potassium levels in blood) (see section “Do not use Furosemida Mabo”).

• increased risk of persistence of the ductus arteriosus when furosemide is administered to premature infants during the first weeks of life.

As with other diuretics, prolonged administration of this medicine may increase the excretion of sodium, chloride, water, potassium, calcium and magnesium. These disturbances may manifest as intense thirst, headache, confusion, muscle cramps, painful muscle contractions, especially in the limbs (tetany), muscle weakness, cardiac rhythm disturbances and gastrointestinal symptoms.

Reporting of adverse effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Furosemide Mabo

Keep this medicine out of the sight and reach of children.

Store in the original packaging to protect it from light.

This medicine does not require any special storage temperature conditions.

Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date refers to the last day of the month indicated.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE Point in your pharmacy. If in doubt, ask your pharmacist how to dispose of unused medicines and containers. This will help protect the environment.

6. Contents of the container and additional information

Composition of Furosemida Mabo

• The active substance is furosemide. Each tablet contains 40 mg of furosemide.
• The other components (excipients) are: maize starch, magnesium carbonate, pregelatinized maize starch, sodium lauryl sulfate, povidone, magnesium stearate.

Appearance of the product and contents of the container

Furosemida Mabo is presented in packs of 30 tablets.

White, round tablets, 8 mm in diameter, scored on one side. The score line is intended to facilitate breaking the tablet into equal doses.

Marketing Authorization Holder

MABO-FARMA S.A.

C/Rejas 2, 1st floor

28821 Coslada (Madrid)

Spain

Manufacturer

INDUSTRIA QUÍMICA Y FARMACÉUTICA VIR, S.A.

C/Laguna 66-70. Polígono Industrial Urtinsa II

28923 Alcorcón (Madrid)

Date of the most recent review of this leaflet: April 2024

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/